Contributors
Jarir At Thobari:
ORCID: http://orcid.org/0000-0002-7035-4846
Role: ConceptualizationRole: Data curationRole: Formal analysisRole: InvestigationRole:
MethodologyRole: Project administrationRole: ValidationRole: Writing – original draft
Cahya Dewi Satria: Role: ConceptualizationRole: InvestigationRole: MethodologyRole: Project administration
Yohanes Ridora: Role: Formal analysisRole: Writing – original draft
Emma Watts: Role: Data curationRole: Formal analysisRole: MethodologyRole: Project administrationRole:
Validation
Amanda Handley: Role: ConceptualizationRole: Data curationRole: MethodologyRole: Project administration
Samad Samad: Role: Investigation
Novilia S. Bachtiar: Role: ConceptualizationRole: MethodologyRole: ResourcesRole: Writing – review & editing
Julie E. Bines:
ORCID: http://orcid.org/0000-0002-5452-6601
Role: ConceptualizationRole: MethodologyRole: ResourcesRole: SupervisionRole: ValidationRole:
Writing – review & editing
Yati Soenarto: Role: ConceptualizationRole: MethodologyRole: SupervisionRole: Writing – review &
editing
Jim P. Buttery: Role: ConceptualizationRole: MethodologyRole: ResourcesRole: SupervisionRole: Writing
– original draftRole: Writing – review & editing
Ricardo Q. Gurgel: Role: Editor
Journal
Journal ID (nlm-ta): PLoS One
Journal ID (iso-abbrev): PLoS ONE
Journal ID (publisher-id): plos
Journal ID (pmc): plosone
Title:
PLoS ONE
Publisher:
Public Library of Science
(San Francisco, CA USA
)
ISSN
(Electronic):
1932-6203
Publication date
(Electronic):
5
August
2019
Publication date Collection: 2019
Volume: 14
Issue: 8
Electronic Location Identifier: e0219097
Affiliations
[1
]
Pediatric Research Office, Department of Pediatrics, Faculty of Medicine, Public Health
and Nursing, Universitas Gadjah Mada, Yogyakarta, Special Region of Yogyakarta, Indonesia
[2
]
Department of Pharmacology and Therapy, Faculty of Medicine, Public Health and Nursing,
Universitas Gadjah Mada, Yogyakarta, Special Region of Yogyakarta, Indonesia
[3
]
RV3 Rotavirus Vaccine Program, Murdoch Children’s Research Institute, Parkville, Victoria,
Australia
[4
]
Medicines Development for Global Health, Melbourne, Victoria, Australia
[5
]
Soeradji Tirtonegoro General Hospital, Klaten, Central Java, Indonesia
[6
]
PT Bio Farma, Bandung, West Java, Indonesia
[7
]
Department of Pediatrics, University of Melbourne, Melbourne, Victoria, Australia
[8
]
Department of Gastroenterology and Clinical Nutrition, Royal Children’s Hospital Melbourne,
Parkville, Victoria, Australia
[9
]
Department of Paediatrics, Monash University, Clayton, Victoria, Australia
[10
]
School of Public Health and Preventive Medicine, Monash University, Clayton, Victoria,
Australia
[11
]
Department of Infection and Immunity, Monash Children’s Hospital, Clayton, Victoria,
Australia
Federal University of Sergipe, BRAZIL
Author notes
Competing Interests: The authors have the following interests: NSB is a paid employee of PT Biofarma. PT
Biofarma is a state-owned company (owned by Indonesia government) that provides all
vaccines for Indonesia National Immunization Program. Additionally, PT Biofarma was
one of the funders for the RV3-BB Phase IIB trial. The trial was a phase IIB trial
and while the RV3-BB rotavirus vaccine is not yet marketed, this vaccine is being
developed with the intention for eventual usage in the national immunization program.
This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Author information
Article
Publisher ID:
PONE-D-19-08447
DOI: 10.1371/journal.pone.0219097
PMC ID: 6681970
PubMed ID: 31381611
SO-VID: a390aeb4-6113-4a58-966e-19916deb81f7
Copyright © © 2019 At Thobari et al
License:
This is an open access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided
the original author and source are credited.
History
Date
received
: 25
March
2019
Date
accepted
: 16
June
2019
Page count
Figures: 1,
Tables: 5,
Pages: 15
Funding
The vaccine company PT Bio Farma provided support for this study in the form of a
salary for the author NSB. The specific role of this author is articulated in the
‘author contributions’ section. Additionally, PT Biofarma was one of the funders of
the RV3-BB Phase IIb trial. Another funding source of the RV3-BB Phase IIb trial was
Murdoch Children’s Research Institute. The funders had roles in the study design,
decision to publish, and preparation of the manuscript.
Categories
Subject:
Research Article
Subject:
Medicine and Health Sciences
Subject:
Pharmacology
Subject:
Drugs
Subject:
Antimicrobials
Subject:
Antibiotics
Subject:
Biology and Life Sciences
Subject:
Microbiology
Subject:
Microbial Control
Subject:
Antimicrobials
Subject:
Antibiotics
Subject:
Medicine and Health Sciences
Subject:
Pharmacology
Subject:
Drugs
Subject:
Antimicrobials
Subject:
Biology and Life Sciences
Subject:
Microbiology
Subject:
Microbial Control
Subject:
Antimicrobials
Subject:
Medicine and Health Sciences
Subject:
Infectious Diseases
Subject:
Infectious Disease Control
Subject:
Vaccines
Subject:
Medicine and Health Sciences
Subject:
Public and Occupational Health
Subject:
Preventive Medicine
Subject:
Prophylaxis
Subject:
Antibiotic Prophylaxis
Subject:
Medicine and Health Sciences
Subject:
Pharmacology
Subject:
Drugs
Subject:
Antimicrobials
Subject:
Antibiotics
Subject:
Penicillin
Subject:
Biology and Life Sciences
Subject:
Microbiology
Subject:
Microbial Control
Subject:
Antimicrobials
Subject:
Antibiotics
Subject:
Penicillin
Subject:
Biology and Life Sciences
Subject:
Microbiology
Subject:
Microbial Control
Subject:
Antimicrobial Resistance
Subject:
Medicine and Health Sciences
Subject:
Pharmacology
Subject:
Antimicrobial Resistance
Subject:
People and Places
Subject:
Population Groupings
Subject:
Age Groups
Subject:
Children
Subject:
Infants
Subject:
People and Places
Subject:
Population Groupings
Subject:
Families
Subject:
Children
Subject:
Infants
Subject:
Research and Analysis Methods
Subject:
Research Design
Subject:
Clinical Research Design
Subject:
Adverse Events
Custom metadata
